[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-366186-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-366186-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","multomic-analysis-reveals-the-potential-of-lag3-as-a-prognostic-and-immune-biomarker-and-its-validation-in-osteosarcoma","Multomic analysis reveals the potential of LAG3 as a prognostic and immune biomarker and its validation in osteosarcoma","","Lymphocyte activation gene 3 (LAG3) is investigated as an immunologic checkpoint candidate and potential biomarker across pan-cancer cohorts and specifically in osteosarcoma. The study performs comprehensive bioinformatics analyses using major public datasets to link LAG3 expression with survival prognosis, tumor microenvironment features, immunotherapy responsiveness, and mechanisms including gene variants and methylation. In osteosarcoma, in vitro functional assays and in vivo xenografts assess proliferation, migration, invasion, and tumor growth, while correlations with immune markers are evaluated. Results indicate LAG3 is upregulated in multiple cancers and relates to stage, diagnosis, prognosis, immune gene abundance, and drug sensitivity.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/multomic-analysis-reveals-the-potential-of-lag3-as-a-prognostic-and-immune-biomarker-and-its-validation-in-osteosarcoma/366186/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/multomic-analysis-reveals-the-potential-of-lag3-as-a-prognostic-and-immune-biomarker-and-its-validation-in-osteosarcoma/366186.png","ImageObject",300,407,{"name":42,"@type":43},"Nguyễn Văn Học","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-24","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",6,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What question does the study address about LAG3?","Question",{"text":63,"@type":64},"The study examines whether LAG3 relates to patient survival prognosis, tumor microenvironment characteristics, immunotherapy responsiveness, and underlying mechanisms, and whether these findings hold for osteosarcoma.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Which datasets and resources were used to analyze LAG3 across cancers?",{"text":68,"@type":64},"The analysis uses pan-cancer resources including TCGA, GTEx, TIMER2, GDSC, CTRP, and TISCH, plus online websites to extract LAG3-related data and evaluate multiple molecular and clinical relationships.",{"name":70,"@type":61,"acceptedAnswer":71},"How were LAG3 functions validated in osteosarcoma?",{"text":72,"@type":64},"Osteosarcoma cell functions were tested with CCK-8, wound healing, and transwell assays, followed by in vivo xenotransplantation to evaluate tumor growth and link LAG3 expression with immune genes.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},366186,1790813522,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":99,"preview_page_count":33,"preview_urls":145},1374402739827,"https://ap-avatar.wpscdn.com/avatar/14000c97e7351f1a627?x-image-process=image/resize,m_fixed,w_180,h_180&k=1787885694763230660","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nMultomic analysis reveals the potential of LAG3 as a prognostic and immune biomarker and its validation in osteosarcoma  \nQianqian Cao1,4, Yuzhe Zhang2,4, Cheng Cheng1, Xiaoyang Wang1, Panlong Fan1, Jincheng Huang1 & Zhipeng Dai1,3􀀍  \nLymphocyte activation gene 3 (LAG3) is a member of the immunoglobulin superfamily and has been implicated in the development, growth, and progression of several cancers. However, the biological role of LAG3 has not been investigated in pan-cancer datasets. We sought to perform a comprehensive bioinformatics analysis of pan-cancer datasets to determine the relationship of LAG3 with patient survival prognosis, tumor microenvironment, immunotherapy responsiveness, and mechanisms regulating tumorigenesis. We used TCGA, GTEx, TIMER2, GDSC, CTRP, and TISCH databases and online websites to extract data on LAG3 in a variety of cancers, and analyzed pan-cancer patient datasets to explore not only the correlation between LAG3 expression and clinical stage, diagnosis, and prognosis of cancers, but also the correlation between LAG3 expression, gene variants, methylation status, tumor stemness, and tumor immunity. The biological functions of LAG3 in osteosarcoma cells were determined by in vitro CCK-8, wound healing and transwell assays. Finally, through in vivo experiments, the study preliminarily explored the impact of LAG3 on osteosarcoma and its correlation with immune genes. Pan-cancer analysis showed that LAG3 expression was up-regulated in a variety of cancers, and the expression of LAG3 was closely related to the clinical stage, diagnosis and prognosis of cancers. GO and KEGG enrichment analyses showed that LAG3 was enriched in inflammatory, metabolic, and immune signaling pathways in a variety of cancers. Meanwhile, LAG3 expression not only has an impact on patient immunotherapy prognosis and immunotherapy response, but also has a significant effect on drug sensitivity. In vitro experiments have shown that LAG3 promotes the proliferation, migration and invasion of osteosarcoma cells. In vivo xenotransplantation experiments further confirmed that LAG3 promotes the growth of osteosarcoma, and the expression of LAG3 is positively correlated with CD8, CD19, and CD68. Our study suggests that LAG3 is a promising marker for cancer diagnosis, prognosis, and treatment.  \nKeywords LAG3, Pan-cancer, Diagnosis, Prognosis, Immune  \nGlobally, cancer has become the leading cause of death, and the number of deaths due to cancer is increasing each year in most countries1. As the state ofthe art in medical diagnostics continues to improve, more and more new cancerous lesions are being detected, and with this comes a growing cancer burden2. Although there are various treatments for cancer including: surgery, chemotherapy, radiation therapy, targeted therapy or immunotherapy, there is still no definitive cure3,4. Pan-cancer analysis provides the most effective understanding of the molecular mechanisms and predictive value of genes in tumor biology, thereby maximizing clinical diagnostic and therapeutic options5–7. Therefore, it is important to analyze potential biomarker genes at the pan-cancer level and explore their association with clinical outcomes in cancer patients.  \nLymphocyte activation gene 3 (LAG3, CD223) is located on chromosome 12 (12p13.32) and encodes a type I transmembrane protein, a member of the immunoglobulin superfamily8. LAG3 consists of three regions, the extracellular, transmembrane and intracellular regions, and its intracellular structural domains are associated  \n1Department of Orthopaedics, Henan Provincial People’s Hospital, Zhengzhou University People’s Hospital, Zhengzhou, Henan, China. 2The First Laboratory of Cancer Institute, The First Hospital of China Medical University, Shenyang, China. 3Department of Orthopaedics, Henan Provincial People’s Hospital, Zhengzhou University People’s Hospital, No. 7, Weiwu Roa","cbCaiu0ZdcN4s9OG","https://ap.wps.com/l/cbCaiu0ZdcN4s9OG","pdf",7445314,24,"English","# Background\n## Cancer burden and need for biomarkers\n# Methods\n## Pan-cancer bioinformatics data sources\n## Osteosarcoma in vitro and in vivo assays\n# Results\n## LAG3 expression patterns across cancers\n## Associations with clinical stage, prognosis, and tumor immunity\n## Functional effects in osteosarcoma\n# Conclusions","[{\"question\":\"What question does the study address about LAG3?\",\"answer\":\"The study examines whether LAG3 relates to patient survival prognosis, tumor microenvironment characteristics, immunotherapy responsiveness, and underlying mechanisms, and whether these findings hold for osteosarcoma.\"},{\"question\":\"Which datasets and resources were used to analyze LAG3 across cancers?\",\"answer\":\"The analysis uses pan-cancer resources including TCGA, GTEx, TIMER2, GDSC, CTRP, and TISCH, plus online websites to extract LAG3-related data and evaluate multiple molecular and clinical relationships.\"},{\"question\":\"How were LAG3 functions validated in osteosarcoma?\",\"answer\":\"Osteosarcoma cell functions were tested with CCK-8, wound healing, and transwell assays, followed by in vivo xenotransplantation to evaluate tumor growth and link LAG3 expression with immune genes.\"}]","Multomic analysis reveals the potential of LAG3 as a prognostic and immune biomarker and its validation in osteosarcoma | PDF",1790164127,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/62d71f56892b3e0a335b4f35dbd644ef.webp",983,1291,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/239d1d9de4d87407d10b5f8ee36a44ca.webp",982,1290,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5b159d8d6021d10531c0b946df8da71e.webp",981,1289,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/16f77ee2439079498ac8bdedd9d1ecdc.webp",980,1287]